Summary of Use during Lactation

No information is available on the use of pegcetacoplan during breastfeeding. The manufacturer recommends that breastfeeding be discontinued during treatment and for 40 days after the last dose. An alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Eculizumab

Substance Name

Pegcetacoplan

CAS Registry Number

2019171-69-6

Drug Class

Breast Feeding

Lactation

Milk, Human

Complement Inactivating Agents